β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits

Molecular Psychiatry

Volumn 9, Issue 10, 2004, Pages 953-961

  Chacon M A ^a   Barria M I ^a   Soto, C ^b   Inestrosa, N C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

sheet breaker peptide; Alzheimer's disease; Amyloid deposits; Spatial memory; Water maze

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BETA SHEET BREAKER PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; BETA SHEET; CONTROLLED STUDY; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HIPPOCAMPUS; HUMANS; INJECTIONS; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MEMORY DISORDERS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; SPATIAL BEHAVIOR; STEREOTAXIC TECHNIQUES;

EID: 6044240725     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001516     Document Type: Article

References (42)

1. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
2. Hardy JL, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
3. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993; 13: 1676-1687.
4. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
6. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408; 982-985.
7. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-8855.
8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2002; 6: 916-919.
9. Check E. Nerve inflammation halts trial for Alzheimer's drug. Nature 2002; 415: 462.
10. Bishop GM, Robinson SR, Smith MA, Perry G, Atwood CS. Call for Elan to publish Alzheimer's trial details. Nature 2002; 416: 677.
11. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staunfenbiel M et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 2002; 298: 1379.
12. Bronfman FC, Garrido J, Alvarez A, Morgan C, Inestrosa NC. Laminin inhibits amyloid-beta-peptide fibrillation. Neurosci Lett 1996; 218: 201-203.
13. Morgan C, Bugueno MP, Garrido J, Inestrosa NC. Laminin affects polymerization, depolymerization and neurotoxicity of Abeta peptide. Peptides 2002; 23: 1229-1240.
14. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185-7188.
15. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 2002; 81: 434-440.
16. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87: 172-181.
17. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997; 94: 4109-1112.
18. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61: 298-305.
19. Kim JE, Lee M. Fullerene inhibits beta-amyloid peptide aggregation. Biochem Biophys Res Commun 2003; 303: 576-579.
20. Luo Y, Smith JV, Paramasivam V, Burdick A, Curry KJ, Buford JP, Khan I, Netzer WJ, Xu H, Butko P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002; 99: 12197-12202, Epub 2002 Sep 04.
21. Kiuchi Y, Isobe Y, Fukushima K. Type IV collagen prevents amyloid beta-protein fibril formation. Life Sci 2002; 70: 1555-1564.
22. Gordon DJ, Sciarretta KL, Meredith SC. Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 2001; 40: 8237-8245.
23. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlstrom AR, Thyberg J, Terenius L, Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996; 271: 8545-8548.
24. Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castano EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822-826.
25. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T. A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002; 137: 676-682.
26. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672-680.
27. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 1999; 5: 343-350.
28. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 1999; 39: 371-382.
29. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J et al. Reduction of amyloid load and cerebral damage in a transgenic mousemodel of Alzheimer's disease by treatment with a β-sheet breaker peptide. FASEB J 2002; 16: 860-862.
30. Morris RGM. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 1984; 11: 47-60.
31. De Ferrari GV, Chacón MA, Barría MI, Garrido JL, Godoy JA, Olivares G et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils. Mol Psychiatry 2003; 8: 195-208.
32. Frick KM, Baxter MG, Markowska AL, Olton DS, Price DL. Age-related spatial reference and working memory deficits assessed in the water maze. Neurobiol Aging 1995; 16: 149-160.
33. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: New York.
34. Elghetany MT, Saleem A. Methods for staining amyloid in tissues: a review. Stain Technol 1988; 63: 201-212.
35. Puchtler H, Sweat F, Levine M. On the binding of Congo Red by amyloid. J Histochem Cytochem 1961; 10: 355-364.
36. Inestrosa N, De Ferrari G, Garrido J, Alvarez A, Olivares G, Barría M et al. Wnt signaling involvement in β-amyloid-dependent neurodegeneration. Neurochem Int 2002; 41: 341-344.
37. Munch G, Robinson SR. Potential neuiotoxic inflammatory responses to Aβ vaccination in humans. J Neural Transm 2002; 109: 1081-1087.
38. Imbimbo BP. Toxicity of β-amyloid vaccination in patients with Alzheimer's disease. Ann Neurol 2002; 51: 794.
39. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-0 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002; 8: 1263-1269.
40. Dodart JC, Bales KR, Cannon KS, Greene SJ, DeMattos RB, Mathis C et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002; 5: 452-157.
41. Soto C, Brañes MC, Alvarez J, Inestrosa NC. Structural determinants of the Alzheimer's amyloid β-peptide. J Neurochem 1994; 63: 1191-1198.
42. Sigurdsson EM, Permanne B, Soto C, Wisniewski T, Frangione B. In vivo reversal of amyloid-β lesions in rat brain. J Neuropathol Exp Neurol 2000; 59: 11-17.